Previous close | 333.71 |
Open | 334.90 |
Bid | 335.91 x 900 |
Ask | 346.63 x 800 |
Day's range | 332.54 - 338.00 |
52-week range | 261.59 - 394.51 |
Volume | |
Avg. volume | 254,812 |
Market cap | 9.348B |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
HERCULES, Calif., August 22, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during Wells Fargo’s 2024 Healthcare Conference on Wednesday, September 4, at 2:15 PM Eastern Time (11:15 AM Pacific Time).
HERCULES, Calif., August 20, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring.
HERCULES, Calif., August 01, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024.